相似文献
1
RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.
Nat Rev Cancer. 2011 Aug 24;11(9):629-43. doi: 10.1038/nrc3120.
2
Regulation of cancer stem cells by RING finger ubiquitin ligases.
Stem Cell Investig. 2014 Feb 9;1:5. doi: 10.3978/j.issn.2306-9759.2014.01.01. eCollection 2014.
3
A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase.
J Biol Chem. 2002 Aug 16;277(33):30388-93. doi: 10.1074/jbc.M203344200. Epub 2002 Jun 4.
4
Identification of Elongin C and Skp1 sequences that determine Cullin selection.
J Biol Chem. 2004 Oct 8;279(41):43019-26. doi: 10.1074/jbc.M408018200. Epub 2004 Jul 27.
5
Recent insight into the role of RING-finger E3 ligases in glioma.
Biochem Soc Trans. 2021 Feb 26;49(1):519-529. doi: 10.1042/BST20201060.
6
The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma.
Int J Cancer. 2015 Jan 15;136(2):249-57. doi: 10.1002/ijc.28717. Epub 2014 Jan 27.
7
Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases.
Cell Res. 2013 May;23(5):599-619. doi: 10.1038/cr.2013.44. Epub 2013 Mar 26.
8
Cdc53/cullin and the essential Hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme Cdc34.
Genes Dev. 1999 Jun 15;13(12):1614-26. doi: 10.1101/gad.13.12.1614.
9
Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.
FEBS Lett. 2012 May 21;586(10):1397-402. doi: 10.1016/j.febslet.2012.03.052. Epub 2012 Apr 3.
10
Following Ariadne's thread: a new perspective on RBR ubiquitin ligases.
BMC Biol. 2012 Mar 15;10:24. doi: 10.1186/1741-7007-10-24.
引用本文的文献
1
Aberrant PJA2-CHRM3 signaling creates a therapeutic vulnerability in gastric tumor.
Br J Cancer. 2025 Aug 26. doi: 10.1038/s41416-025-03145-8.
2
DNA damage response inhibition is an early event in cadmium-induced breast carcinogenesis.
Toxicol Appl Pharmacol. 2025 Sep;502:117439. doi: 10.1016/j.taap.2025.117439. Epub 2025 Jun 10.
3
Cysteine-rich zinc finger proteins and the nuclear factor kappa-B pathway.
Front Chem Biol. 2024;3. doi: 10.3389/fchbi.2024.1503390. Epub 2024 Dec 19.
4
Research status and frontiers in liver cancer immunotherapy: a bibliometric perspective on highly cited literature.
Front Oncol. 2025 Apr 10;15:1587252. doi: 10.3389/fonc.2025.1587252. eCollection 2025.
5
Neddylation and Its Target Cullin 3 Are Essential for Adipocyte Differentiation.
Cells. 2024 Oct 5;13(19):1654. doi: 10.3390/cells13191654.
6
Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis.
Commun Biol. 2024 Oct 14;7(1):1322. doi: 10.1038/s42003-024-06899-8.
7
USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 Deubiquition.
Adv Sci (Weinh). 2024 Sep;11(34):e2401171. doi: 10.1002/advs.202401171. Epub 2024 Jul 8.
8
The cuproptosis-related gene UBE2D2 functions as an immunotherapeutic and prognostic biomarker in pan-cancer.
Clin Transl Oncol. 2024 Oct;26(10):2718-2737. doi: 10.1007/s12094-024-03495-4. Epub 2024 May 4.
9
Role of microRNA-363 during tumor progression and invasion.
J Physiol Biochem. 2024 Aug;80(3):481-499. doi: 10.1007/s13105-024-01022-1. Epub 2024 May 1.
10
One-carbon metabolism nutrients impact the interplay between DNA methylation and gene expression in liver, enhancing protein synthesis in Atlantic salmon.
Epigenetics. 2024 Dec;19(1):2318517. doi: 10.1080/15592294.2024.2318517. Epub 2024 Feb 25.
本文引用的文献
1
COP1 is a tumour suppressor that causes degradation of ETS transcription factors.
Nature. 2011 May 15;474(7351):403-6. doi: 10.1038/nature10005.
2
MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.
Mol Cancer. 2011 May 3;10:49. doi: 10.1186/1476-4598-10-49.
3
Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
Angiogenesis. 2011 Sep;14(3):255-66. doi: 10.1007/s10456-011-9210-8. Epub 2011 Apr 12.
4
Proteasome inhibitors in cancer therapy.
J Cell Commun Signal. 2011 Jun;5(2):101-10. doi: 10.1007/s12079-011-0121-7. Epub 2011 Jan 31.
5
Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice.
J Clin Invest. 2011 Apr;121(4):1329-43. doi: 10.1172/JCI45784. Epub 2011 Mar 14.
6
BIM(EL), an intrinsically disordered protein, is degraded by 20S proteasomes in the absence of poly-ubiquitylation.
J Cell Sci. 2011 Mar 15;124(Pt 6):969-77. doi: 10.1242/jcs.058438.
7
Hallmarks of cancer: the next generation.
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
8
Cancer predisposing BARD1 mutations in breast-ovarian cancer families.
Breast Cancer Res Treat. 2012 Jan;131(1):89-97. doi: 10.1007/s10549-011-1403-8. Epub 2011 Feb 23.
9
Essential role of E3 ubiquitin ligase activity in Cbl-b-regulated T cell functions.
J Immunol. 2011 Feb 15;186(4):2138-47. doi: 10.4049/jimmunol.1003390. Epub 2011 Jan 19.
10
SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype.
Nat Genet. 2011 Feb;43(2):138-41. doi: 10.1038/ng.751. Epub 2011 Jan 16.
Zotero 插件